Processa Pharmaceuticals, Inc. (PCSA)
2.02
-0.14
(-6.48%)
USD |
NASDAQ |
Sep 09, 11:41
Processa Pharmaceuticals Net Income (Quarterly) : -3.266M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.266M |
| March 31, 2026 | -3.377M |
| December 31, 2025 | -3.359M |
| September 30, 2025 | -3.437M |
| June 30, 2025 | -3.934M |
| March 31, 2025 | -2.834M |
| December 31, 2024 | -2.729M |
| September 30, 2024 | -3.385M |
| June 30, 2024 | -3.010M |
| March 31, 2024 | -2.726M |
| December 31, 2023 | -2.405M |
| September 30, 2023 | -2.082M |
| June 30, 2023 | -2.613M |
| March 31, 2023 | -4.022M |
| December 31, 2022 | -13.01M |
| September 30, 2022 | -6.020M |
| June 30, 2022 | -5.164M |
| March 31, 2022 | -3.227M |
| December 31, 2021 | -3.184M |
| September 30, 2021 | -2.987M |
| June 30, 2021 | -3.157M |
| March 31, 2021 | -2.100M |
| December 31, 2020 | -14.36M |
| September 30, 2020 | -3.071M |
| June 30, 2020 | -0.7334M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.8743M |
| December 31, 2019 | -1.281M |
| September 30, 2019 | -0.8635M |
| June 30, 2019 | -0.9691M |
| March 31, 2019 | -0.7508M |
| December 31, 2018 | -0.6092M |
| September 30, 2018 | -0.8528M |
| June 30, 2018 | -1.206M |
| March 31, 2018 | -1.097M |
| September 30, 2017 | -0.7116M |
| June 30, 2017 | -0.2784M |
| March 31, 2017 | -0.2324M |
| December 31, 2016 | -0.0908M |
| September 30, 2016 | -0.0683M |
| June 30, 2016 | -0.0465M |
| March 31, 2016 | -0.1316M |
| September 30, 2015 | -0.2957M |
| June 30, 2015 | -1.940M |
| March 31, 2015 | -0.4924M |
| December 31, 2014 | -1.539M |
| September 30, 2014 | -0.792M |
| June 30, 2014 | -0.8512M |
| March 31, 2014 | -1.344M |
| December 31, 2013 | -0.8069M |
| September 30, 2013 | -0.7188M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.266M |
| EPS Diluted (Quarterly) | -1.187 |
| Enterprise Value | 5.837M |
| Earnings Yield | -276.7% |
| Normalized Earnings Yield | -270.16 |